Sisram Medical Ltd
復銳醫療科技有限公司*

(Incorporated in Israel with limited liability)

(Stock Code: 1696)

APPOINTMENT OF DIRECTOR

The board of directors (the "**Board**") of Sisram Medical Ltd (the "**Company**", together with its subsidiaries, the "**Group**") announces that, with effect from March 19, 2025, Mr. Jiahong Li ("**Mr. Li**") has been appointed as an executive director of the Company.

Mr. Li, aged 46, joined the Group as the chief financial officer of the Company on October 29, 2024. He is responsible for the financial operation as well as financing and investment activities of the Group. Mr. Li holds a master of business administration from National University of Singapore and a bachelor of economics from University of International Business & Economics, China. Mr. Li is a Certified Management Accountant of the United States, a Chartered Global Management Accountant and a fellow of the Chartered Institute of Management Accountants of the United Kingdom, the Institute of Public Accountant of Australia, and the Institute of Financial Accountants of the United Kingdom. He has over 25 years of experience in financial management, strategy formulation and execution, and M&A gained from Fortune 500 multinational and leading start-up companies in Telecom, Consumer Care and Healthcare industry. Prior to joining the Group, Mr. Li was the Executive Director, Vice President and Head of Finance and Government Affairs of EdiGene Inc from 2021 to 2024, the Chief Financial Officer of Varian Medical Systems Asia Pacific from 2013 to 2021, the Regional Finance Controller of Johnson & Johnson Asia Pacific from 2010 to 2013 and served various financial roles at Motorola from 2000 to 2010.

Save as disclosed above, Mr. Li did not hold any directorship in listed public companies in the three years preceding the date of this announcement, nor does he has any relationship with any other director or senior management of the Company, or substantial or controlling shareholders of the Company.

As at the date of this announcement, Mr. Li does not have any interest in the shares or underlying shares of the Company and its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance.

Mr. Li has entered into a letter of appointment with the Company for a period commencing from March 19, 2025 and will continue thereafter unless terminated by either party giving to each other three months' written notice in advance, subject to the provision of retirement and rotation of directors under the articles of association of the Company. Pursuant to the articles of association of the Company, Mr. Li will hold office as an executive director of the Company until the forthcoming annual general meeting of the Company and will then stand for re-election at that meeting. Mr. Li will not receive any emolument from the Company for acting as an executive director of the Company.

Save as disclosed above, there is no other matter that needs to be brought to the attention of the shareholders of the Company in connection with Mr. Li's appointment and there is no other information that should be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The Board would like to extend their warm welcome to Mr. Li for joining the Board.

On behalf of the Board
Sisram Medical Ltd
復銳醫療科技有限公司*
Yi LIU
Chairman

Hong Kong, March 19, 2025

As at the date of this announcement, the Board of the Company comprises Mr. Yi LIU, Mr. Lior Moshe DAYAN and Mr. Jiahong LI as Executive Directors; Mr. Yifang WU and Ms. Rongli FENG as Non-Executive Directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as Independent Non-executive Directors.

* *for identification purpose only*